163 related articles for article (PubMed ID: 37551947)
1. Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma.
Bobillo S; Wilson MR; Cwynarski K
Curr Opin Oncol; 2023 Sep; 35(5):382-388. PubMed ID: 37551947
[TBL] [Abstract][Full Text] [Related]
2. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
[TBL] [Abstract][Full Text] [Related]
4. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
5. [Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2023; 64(6):490-496. PubMed ID: 37407473
[TBL] [Abstract][Full Text] [Related]
6. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
[TBL] [Abstract][Full Text] [Related]
7. Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
Wilson MR; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Lees C; Fox C; Preston G; Ahearne M; Strüßmann T; Clavert A; Rusconi C; Ku M; Khwaja J; Narkhede M; Lewis K; Durot E; Smith J; Renaud L; Ferreri AJM; El-Galaly T; Cwynarski K; McKay P; Eyre TA
Am J Hematol; 2024 Feb; 99(2):E46-E50. PubMed ID: 38037530
[No Abstract] [Full Text] [Related]
8. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
[TBL] [Abstract][Full Text] [Related]
10. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
11. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA; Kirkwood AA; Wolf J; Hildyard C; Mercer C; Plaschkes H; Griffith J; Fields P; Gunawan A; Oliver R; Booth S; Martinez-Calle N; McMillan A; Bishton M; Fox CP; Collins GP; Hatton CSR
Br J Haematol; 2019 Oct; 187(2):185-194. PubMed ID: 31222719
[TBL] [Abstract][Full Text] [Related]
12. Model for Predicting Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Discussion of Prophylaxis Measures.
Cui JY; Liu YF; Gao B; Mi L; Deng LJ; Zhu J; Hou SL
World Neurosurg; 2023 Nov; 179():e387-e396. PubMed ID: 37652134
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
Eyre TA; Djebbari F; Kirkwood AA; Collins GP
Haematologica; 2020 Jul; 105(7):1914-1924. PubMed ID: 31488560
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?
Lantz J; Portell CA; Ayers EC
Blood Rev; 2023 Sep; 61():101101. PubMed ID: 37258362
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Bobillo S; Joffe E; Sermer D; Mondello P; Ghione P; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Batlevi CL; Moskowitz A; Noy A; Owens CN; Palomba ML; Straus D; von Keudell G; Dogan A; Zelenetz AD; Seshan VE; Younes A
Blood Cancer J; 2021 Jun; 11(6):113. PubMed ID: 34135307
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis.
Ho G; Tan C; de Mel S; Poon L; Chan EHL; Lee J; Liu X; Chng WJ; Chee YL; Soon YY; Jeyasekharan AD
Crit Rev Oncol Hematol; 2021 Nov; 167():103507. PubMed ID: 34656744
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
18. Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.
Kuitunen H; Kaprio E; Karihtala P; Makkonen V; Kauppila S; Haapasaari KM; Kuusisto M; Jantunen E; Turpeenniemi-Hujanen T; Kuittinen O
Ann Hematol; 2020 Aug; 99(8):1823-1831. PubMed ID: 32577843
[TBL] [Abstract][Full Text] [Related]
19. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
20. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Holte H; Leppä S; Björkholm M; Fluge O; Jyrkkiö S; Delabie J; Sundström C; Karjalainen-Lindsberg ML; Erlanson M; Kolstad A; Fosså A; Ostenstad B; Löfvenberg E; Nordström M; Janes R; Pedersen LM; Anderson H; Jerkeman M; Eriksson M
Ann Oncol; 2013 May; 24(5):1385-92. PubMed ID: 23247661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]